These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11020127)

  • 1. Protease inhibitor-induced carbamazepine toxicity.
    Berbel Garcia A; Latorre Ibarra A; Porta Etessam J; Martinez Salio A; Perez Martinez D; Siaz Diaz R; Toledo Heras M
    Clin Neuropharmacol; 2000; 23(4):216-8. PubMed ID: 11020127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-induced carbamazepine toxicity.
    Mateu-de Antonio J; Grau S; Gimeno-Bayón JL; Carmona A
    Ann Pharmacother; 2001 Jan; 35(1):125-6. PubMed ID: 11197575
    [No Abstract]   [Full Text] [Related]  

  • 4. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz.
    Burman W; Orr L
    AIDS; 2000 Dec; 14(17):2793-4. PubMed ID: 11125901
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential interaction between ritonavir and carbamazepine.
    Kato Y; Fujii T; Mizoguchi N; Takata N; Ueda K; Feldman MD; Kayser SR
    Pharmacotherapy; 2000 Jul; 20(7):851-4. PubMed ID: 10907977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitors and anticonvulsants.
    Brooks J; Daily J; Schwamm L
    AIDS Clin Care; 1997 Nov; 9(11):87, 90. PubMed ID: 11364776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
    Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
    Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
    Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
    Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential fluconazole-induced carbamazepine toxicity.
    Nair DR; Morris HH
    Ann Pharmacother; 1999; 33(7-8):790-2. PubMed ID: 10466905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carbamazepine and clarithromycin: a clinically relevant drug interaction].
    Gélisse P; Hillaire-Buys D; Halaili E; Jean-Pastor MJ; Vespignan H; Coubes P; Crespel A
    Rev Neurol (Paris); 2007 Nov; 163(11):1096-9. PubMed ID: 18033049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
    Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
    Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine-phenprocoumon interaction.
    Böttcher T; Buchmann J; Zettl UK; Benecke R
    Eur Neurol; 1997; 38(2):132-3. PubMed ID: 9286639
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
    Fitzsimmons ME; Collins JM
    Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
    J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug interactions with antiretroviral agents].
    Furlan V; Taburet AM
    Therapie; 2001; 56(3):267-71. PubMed ID: 11475806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticonvulsant and antiretroviral interactions.
    Liedtke MD; Lockhart SM; Rathbun RC
    Ann Pharmacother; 2004 Mar; 38(3):482-9. PubMed ID: 14970370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report.
    Gaida-Hommernick B; Rieck K; Runge U
    Epilepsia; 2001 Jun; 42(6):793-5. PubMed ID: 11422339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
    Knox TA; Oleson L; von Moltke LL; Kaufman RC; Wanke CA; Greenblatt DJ
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):358-68. PubMed ID: 19186349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.